medicines company (MDCO:NASDAQ GS)
Steven R. Steinhubl M.D., FACC
Global Vice President of Thrombosis, The Medicines Company
|Age||Total Calculated Compensation||This person is connected to 3 board members in 1 different organizations across 3 different industries.|
See Board Relationships
Dr. Steven R. Steinhubl, M.D., FACC has been Global Vice President of Thrombosis of Medicines Co. since February 2008. Dr. Steinhubl is responsible for the development programs for both cangrelor, an investigational antiplatelet agent, and Angiox(R) (bivalirudin) from the European headquarters in Zurich, Switzerland. Dr. Steinhubl joined Medicines Co. as Global Vice President, of Thrombosis. Dr. Steinhubl is a director of digital medicine at the Scripps Translational ...
8 Sylvan WayPhone: 973-290-6000
Parsippany, New Jersey 07054
Board Members Memberships*
Unknown/Other Education 1988
St Louis University School Of Medicine
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|James Patrick Mackin||Chief Executive Officer, President and Director|
|Robert L. Parkinson Jr.||Chairman, Chief Executive Officer and President|
Baxter International Inc.
|Andrew Philip Witty||Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee|
|John C. Lechleiter Ph.D.||Chairman, Chief Executive Officer and President|
Eli Lilly and Company
|Albert D. Friesen Ph.D.||Founder, Chairman and Chief Executive Officer|
|--||Compensation as of Fiscal Year --.|